Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalence of baseline brain metastases.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC's $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat's value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Analysts
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright
From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 58.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside
ORIC Pharmaceuticals is advancing two best-in-class small molecule inhibitors targeting resistance mechanisms in prostate and lung cancer. ORIC's $413 million cash position, bolstered by a 2025 equity raise, secures operations and Phase 3 trial funding into the second half of 2028. Rinzimetostat and enozertinib have shown promising efficacy and safety in early trials, with both candidates entering registrational Phase 3 studies by 2026.
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know
Oric Pharmaceuticals (ORIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
